礼来第一款超级“重磅炸弹”诞生,替尔泊肽收入狂飙164亿美元

医药魔方
06 Feb

2月6日,礼来发布2024年业绩,全年营收450.43亿美元,同比增长32%;研发投入109.906亿美元,同比增长18%。中国区收入16.60亿美元,同比增长9%。从治疗领域来看,礼来目前聚焦糖尿病、肿瘤、免疫、神经四大疾病领域。糖尿病板块是礼来的核心业务,在度拉糖肽和替尔泊肽等主力产品的助力下,礼来在糖尿病领域的巨头地位稳固如山。Trulicity(度拉糖肽)、Mounjaro(替尔泊肽)、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10